Here we offer access to some of our recent publications, including the Discussion Paper series issued by our Institute.
Please visit us again as we will continuously update and extend this website.
Recent Scientific Presentations
MedTech Dialogue Meeting
Mannheim / Germany, March 23, 2017
Health Technology Assessment (HTA) for Medical Products – How to Cope with the Increasing Regulatory Burden?
Download (1.3 MiB)
19th Annual European Congress of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
Vienna / Austria, October 29 - November 02, 2016
Different Methods, Different Results? Comparing Health Technology Assessments in the United Kingdom and Germany.
Value in Health 19  (2016) A494
Abstract (91.5 KiB)
Poster Presentation (75.1 KiB)
The European Social Preference Measurement (ESPM) Study: Conceptual Considerations and Implementation.
Value in Health 19  (2016) A508
Abstract (81.9 KiB)
Poster Presentation (593.9 KiB)
Drugs for Rare and Ultra-Rare Diseases in Europe: Analysis of Budget Impact and Cost Drivers.
Value in Health 19  (2016) A598
Abstract (79.7 KiB)
Poster Presentation (176.2 KiB)
8th European Conference on Rare Diseases & Orphan Products (ECRD 2016)
Edinburgh / Scotland, May 26-28, 2016
The European Social Preferences Measurement (ESPM) study project: social cost value analysis, budget impact, commercial life cycle revenue management, and the economics of biopharmaceutical Research & Development (R&D)
Orphanet Journal of Rare Diseases 11 (Suppl 1), 2016: 143
Published November 2016
Presentation (455.0 KiB)
Abstract (510.9 KiB)
EURORDIS Roundtable of Companies (ERTC) Meeting:
Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies,
Brussels / Belgium, February 24, 2016
The Social Value of Orphan Medicinal Products (OMPs): European Social Preferences Measurement (ESPM) Study Project
Presentation (973.7 KiB)
German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
Heidelberg / Germany, January 21, 2016
Sprengt die Krebstherapie das Gesundheitssystem?
[Can We Afford the Cost of Cancer Care?]
Presentation (752.6 KiB)
Health Economics Global Congress 2015 Europe,
London / England, December 07, 2015
“The Burning Platform”: Credibility of Corporate Health Economics.
Presentation (3.0 MiB)
2nd International Scientific and Practical Conference
“Health Technology Assessment: Ways of Development in Russia”*,
Moscow / Russia, November 02, 2015
Multi-Criteria Decision Analysis (MCDA) as a Tool of HTA
Presentation (550.6 KiB)
*Conference organized by Ministry of Health, Ministry of Finance, and Ministry of Industry and Trade of the Russian Federation, Council of the Federation Committee on Social Policy of the Federal Assembly of the Russian Federation, Federal Compulsory Medical Insurance Fond, Skolkovo Foundation, FSBI “Center of Expertise and Quality Control of Medicines” of the Ministry of health of the Russian Federation, FSBI “Financial Research Institute” of the Ministry of Health of the Russian Federation, Russian Presidential Academy of National Economy and Public Administration, and International Society for Pharmacoeconomics and Outcomes Research
2015 HTAi International Conference,
Oslo / Norway, June 14-17, 2015.
Improving the Usefulness of Health Economic Evaluations for Decision Makers: Social Value and the Case of Interventions for Rare and Ultra-Rare Disorders (URDs).
Invited Panel Workshop (moderated by Deborah Marshall, Calgary)
Presentation (1.3 MiB)
Communicating values and ethics across the healthcare decisionmaking continuum: where are we and what holistic multicriteria brings?
Poster (159.5 KiB)
ISPOR 20th Annual International Meeting,
Philadelphia, PA / USA, May 16-20, 2015
The Controversial Role of Cost-Effectiveness Analyses (CEA) and Incremental Cost-Effectiveness Ratio (ICER) Thresholds in Value-Based Assessments (VBA) of Health Technologies: What are the Future Challenges?
Invited Presentation to an ISPOR Issue Panel (discussants, Z. Khan, M. Schlander, R. Akehurst, J. Proach), May 19, 2015
Abstract (70.5 KiB)
Presentation (278.8 KiB)
German Central ADHD Network, State-of-the-Art Meeting 2014 (Zentrales ADHS-Netz, Statuskonferenz ADHS)
(Chairs: M. Döpfner, T. Banaschewski, M. Rösler, K. Skrodzki),
Berlin / Germany, December 08/09, 2014
ADHD Pharmacotherapy: Prescription Rates, Utilization, Trends
[Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) – Pharmakotherapie: Verschreibungsraten, Versorgungsraten, Entwicklung.]
Abstract (499.7 KiB)
17th Annual European Congress of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
Amsterdam / The Netherlands, November 8-12, 2014
The Evaluation of Economic Methods to Assess the Social Value of Medical Interventions for Ultra-Rare Disorders (URDs).
Value in Health 17  (2014) A324
Abstract (94.4 KiB)
Presentation (197.9 KiB)
Budget Impact Analysis of Drugs for Ultra-Rare Non-Oncological Diseases in Europe.
Value in Health 17  (2014) A525
Abstract (92.6 KiB)
Presentation (606.2 KiB)
Rare Diseases and Orphan Drug Symposium and Orphan Drug Regulation Workshop
(Ilac Bilincini Gelistirme ve Akilci Ilac Dernegi)
Belek, Antalya / Turkey, September 13 (/14), 2014
Interventions for Rare / Ultra-Rare Disorders and the Logic of Cost Effectiveness.
Presentation (651.3 KiB)
11th Annual Meeting of Health Technology Assessment International (HTAi)
Washington, DC, June 15-18, 2014:
“Optimizing Patient-Centered Care in an Era of Economic Uncertainty”
Health Technology Assessment (HTA) in Switzerland: The “SwissHTA” Multi-Stakeholder Consensus.
Oral presentation, session on “How to Improve Resource Allocation”, June 16, 2014
Abstract (81.5 KiB)
Presentation (991.1 KiB)
Interventions for Ultra-Rare Disorders (URDs): How to Assess “Value for Money”?
Oral presentation, session on “Valuing Health – Past, Present, and Future”, June 16, 2014
Abstract (84.7 KiB)
Presentation (533.2 KiB)
16th Annual European Congress of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
Dublin / Ireland, November 2-6, 2013
The Measurement of Health-Related Quality of Life: German Findings from the Multi-Instrument Comparison (MIC) Study.
Value in Health 16  (2013) A330.
Abstract (96.2 KiB)
Presentation (460.0 KiB)
Incremental Cost per Quality-Adjusted Life Year Gained? The Need for Alternative Methods to Evaluate Medical Interventions for Ultra-Rare Disorders.
Value in Health 16  (2013) A324.
Abstract (95.3 KiB)
Presentation (502.7 KiB)
15th International Congress of the European Society for Child and Adolescent Psychiatry (ESCAP)
Dublin / Ireland, July 6-10, 2013
Attention-Deficit Hyperactivity Disorder (ADHD), 2003-2009: A Longitudinal Analysis of Prevalence, Health Care and Direct Cost Based upon Administrative Data from Nordbaden / Germany. Symposium.
European Child + Adolescent Psychiatry 22 [Suppl. 2] (2013) S102 (Abstract No. S2-06-05).
Abstract (118.6 KiB)
Symposium Presentations (2.8 MiB)
Mental Health Care Research in Germany: Sociodemographic Characteristics of the Nordbaden Database.
European Child + Adolescent Psychiatry 22 [Suppl. 2] (2013) S100 (Abstract No. S2-06-01).
Abstract (116.3 KiB)
The Rising Administrative Prevalence of Attention-Deficit Hyperactivity Disorder (ADHD) in Nordbaden /Germany and Specialist Involvement in Health Care Provision.
European Child + Adolescent Psychiatry 22 [Suppl. 2] (2013) S101-102 (Abstract No. S2-06-04).
Abstract (119.2 KiB)
The Evolving Treatment Patterns for Attention-Deficit Hyperactivity Disorder (ADHD) in Nordbaden /Germany: A Retrospective Study Based upon Administrative Data, Years 2003-2009.
European Child + Adolescent Psychiatry 22 [Suppl. 2] (2013) S101 (Abstract No. S2-06-03).
Abstract (119.6 KiB)
The Medical Cost Attributable to Attention-Deficit Hyperactivity Disorder (ADHD) in Nordbaden / Germany: A Study From a Health Care Payer’s Perspective Based on Claims Data.
European Child + Adolescent Psychiatry 22 [Suppl. 2] (2013) S100-101 (Abstract No. S2-06-02).
Abstract (120.3 KiB)
4th World Congress on ADHD, From Childhood to Adult Disease
Milan / Italy, June 6-9, 2013
Costs and Benefits of Attention-Deficit Hyperactivity Disorder (ADHD).
[Invited Plenary Presentation]
Attention-Deficit/Hyperactivity Disorders (ADHD) 5  (2013) 113.
Presentation (573.9 KiB)
3rd European Pricing Platform (EPP) Life Sciences Forum
Montreux / Switzerland, June 5-6, 2013
Europe – Problem Child or Rising Star? Outlook and Opportunities for Growth.
[Invited Keynote Presentation]
Presentation (988.1 KiB)
15th Annual European Congress of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
Berlin / Germany, November 3-7, 2012
“Fairness First?” – Social versus Individual Preferences.
[Third Plenary Session]
Introductory Presentation (145.6 KiB)
The Swiss Health Technology Assessment (HTA) Consensus: Guiding Principles.
Value in Health 15  (2012) A319.
Abstract (488.1 KiB)
Poster Presentation (877.3 KiB)
9th European Congress of Health Economics (ECHE 2012)
Zurich, Switzerland, July 18-21, 2012
Will Progress in Applied Health Economics Depend on a New Evaluation Paradigm?
Poster Presentation (315.5 KiB)
14th Annual European Congress of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
Madrid / Spain, November 5-8, 2011
The Cost Effectiveness of Clinically Proven Treatment Strategies for ADHD in Adult Patients.
Value in Health 14  (2011) A403.
Abstract (112.9 KiB)
Poster Presentation (212.3 KiB)
Increasing Use of Medication for Treatment of Attention Deficit hyperactivity Disorder (ADHD) in Germany between 2003 and 2009.
Value in Health 14  (2011) A300.
Abstract (112.3 KiB)
Poster Presentation (214.2 KiB)
3rd International Congress on ADHD – From Childhood to Adult Disease
Berlin / Germany, May 26-29, 2011
Does One out of Seven Nine-Year Old Boys Suffer from Attention-Deficit/Hyperactivity Disorder (ADHD)? The Increasing Administrative Prevalence of ADHD in Germany, 2003 – 2009.
Abstract (489.6 KiB)
Poster Presentation (251.4 KiB)
2nd Joint Conference “Health Care Challenges”
by Institut der deutschen Wirtschaft (Cologne / Germany) & Istituto Bruno Leoni (Milan / Italy)
Berlin / Germany, May 3, 2011
Pharmaceuticals – Keeping the Industry Competitive. A Perspective from Germany.
Invited Presentation (2.2 MiB)